Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort. by Fisher, G et al.
Fisher, G; Yang, ZH; Kudahetti, S; Mller, H; Scardino, P; Cuzick,
J; Berney, DM (2013) Prognostic value of Ki-67 for prostate cancer
death in a conservatively managed cohort. British journal of cancer,
108 (2). pp. 271-7. ISSN 0007-0920 DOI: 10.1038/bjc.2012.598
Downloaded from: http://researchonline.lshtm.ac.uk/629322/
DOI: 10.1038/bjc.2012.598
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Prognostic value of Ki-67 for prostate cancer
death in a conservatively managed cohort
G Fisher1, Z H Yang1, S Kudahetti2, H Møller3, P Scardino4, J Cuzick1, D M Berney*,2 and on behalf of the
Transatlantic Prostate Group
1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London EC1M 6BQ,
UK; 2Department of Molecular Oncology, Barts Cancer Centre, Barts and the London, School of Medicine and Dentistry, Queen
Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK; 3King’s College London, Thames Cancer Registry,
London, UK and 4Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Background: Standard clinical parameters cannot accurately differentiate indolent from aggressive prostate cancer. Our previous
work showed that immunohistochemical (IHC) Ki-67 improved prediction of prostate cancer death in a cohort of conservatively
treated clinically localised prostate cancers diagnosed by transurethral resection of the prostate (TURP). Here, we present results in
a more clinically relevant needle biopsy cohort.
Methods: Biopsy specimens were microarrayed. The percentage of Ki-67 positively stained malignant cells per core was
measured and the maximum score per individual used in analysis of time to death from prostate cancer using a Cox proportional
hazards model.
Results: In univariate analysis (n¼ 293), the hazard ratio (HR) (95% confidence intervals) for dichotomous Ki-67 (p10%,410%) was
3.42 (1.76, 6.62) w2 (1 df)¼ 9.8, P¼ 0.002. In multivariate analysis, Ki-67 added significant predictive information to that provided by
Gleason score and prostate-specific antigen (HR¼ 2.78 (1.42, 5.46), w2 (1 df)¼ 7.0, P¼ 0.008).
Conclusion: The IHC Ki-67 scoring on prostate needle biopsies is practicable and yielded significant prognostic information. It was
less informative than in the previous TURP cohort where tumour samples were larger and more comprehensive, but in more
contemporary cohorts with larger numbers of biopsies per patient, Ki-67 may prove a more powerful biomarker.
The optimal treatment for organ confined prostate cancer
remains a challenge for health professionals worldwide. While
potentially curative treatments exist, they are associated with
substantial morbidity and the five-fold difference between prostate
cancer incidence and mortality in many developed countries
indicates that there is substantial over treatment of indolent
neoplasms (Etzioni et al, 2002). As serum prostate-specific antigen
(PSA) testing becomes more common, the incidence of prostate
cancer will continue to rise further, and a greater proportion of
tumours will be indolent and potentially manageable by active
surveillance.
The differentiation of indolent from aggressive prostate cancer
was recently ranked top priority for research, by a consultation
conducted by the James Lind Alliance (Lophatananon et al, 2011).
Management of the disease relies largely on standard clinical
factors including Gleason score, PSA level, clinical stage and
measures of tumour extent on biopsy and imaging, but these are
clearly inadequate and better markers of prognosis are needed.
Molecular biomarkers in tissue, urine, or serum have
proven difficult to validate. Many biomarkers have shown
association with Gleason score and some have also been associated
with outcome after radical treatment (D’Amico et al, 2008; Vergis
et al, 2010; Kristiansen, 2012), but comparatively little work has
been done on cohorts of prostate cancer managed conservatively,
especially when the diagnosis was made by a needle biopsy where
tissue is limited.
The most promising immunohistochemical (IHC) biomarker
identified so far is Ki-67, a marker of cell proliferation. As the
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grading system in prostate cancer (unlike many other cancers)
does not consider the proliferation rate of the cells, it is possible
that measuring the cell proliferation rate in prostate tumours
could yield additional prognostic information. Ki-67 (1% cutoff)
was shown to be useful in predicting time to radical treatment,
in a biopsy tissue microarray study of 60 patients on active
surveillance (Jhavar et al, 2009) and a range of studies in cohorts
with larger radical prostatectomy (RP) or transurethral resection of
the prostate (TURP) diagnostic samples, reviewed by Kristiansen
(2012), have shown that Ki-67 IHC measurements can significantly
predict prostate cancer outcome. There has been little consensus in
the choice of Ki-67 cutoff points, and predictions of progression, in
terms of biochemical recurrence following radical treatments,
have been based on a wide range from 2.4% to 26%, while a range
from 3% to10.3% has shown the prognostic significance of Ki-67 in
both overall and disease-specific survival. Detailed results are
provided in Supplementary Table 1. There is evidence in the
existing literature (Stattin et al, 1997; Cowen et al, 2002;
Rubin et al, 2002; Sebo et al, 2002; Pollack et al, 2003; Li et al,
2004; Pollack et al, 2004; Rubio et al, 2005; Gunia et al, 2008;
Laitinen, 2008; Berney et al, 2009; Khor et al, 2009; Zellweger et al,
2009) that Ki-67 can improve predictions of prostate cancer
outcome based on standard factors alone, in men treated
conservatively or radically. Multivariate HRs for prostate cancer-
specific survival and prostate cancer recurrence are shown in
Figure 1A and B, respectively, and additional information is
summarised in Table 1.
Although molecular mRNA markers of cell proliferation gene
expression (Cuzick et al, 2012) have shown promise, they are more
technically demanding and expensive to perform.
Our previous work, on the Trans Atlantic Prostate Group
cohort of conservatively managed prostate cancers diagnosed by
TURP showed that Ki-67 was an independent prognostically
significant marker when PSA, Gleason score, and tumour extent
were also considered (Berney et al, 2009). However, since TURP is
no longer a common means of diagnosis of prostate cancer, any
practicable test would need to be useful on needle biopsy
specimens. Here, we report results of such an investigation.
MATERIALS AND METHODS
Patients. Potential cases of prostate cancer were identified from
six cancer registries in Great Britain. Case notes from collaborating
hospitals were reviewed, and full details of these patients have been
previously reported (Cuzick et al, 2006). Men were included in this
study if they had clinically localised prostate cancer, diagnosed by
use of needle biopsy between 1990 and 1996 (inclusively), were
younger than 76 years at the time of diagnosis, and had a baseline
PSA measurement. Patients with PSA values greater than
100 ngml 1 were excluded as likely to have metastatic disease.
Patients treated with RP or radiation therapy, or who died or
showed evidence of metastatic disease within 6 months of
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Figure 1. Hazard ratio for Ki-67 in multivariate analysis after adjustment for covariates, in the existing literature, for (A) prostate cancer-specific
survival (I-squared¼ 7.5%, P¼ 0.371) and (B) prostate cancer recurrence (I-squared¼ 61.9%, P¼0.007). The area of the box is proportional to the
amount of information available, and the horizontal bars represent 95% confidence intervals.
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diagnosis were also excluded, as were men who had hormone
therapy before the diagnostic biopsy.
Original histological specimens from the diagnostic procedure
were requested, collected, and centrally reviewed by a panel of
expert urological pathologists to confirm the diagnosis and to
reassign Gleason scores by use of a contemporary and consistent
interpretation of the Gleason scoring system (Epstein et al, 2005).
Follow-up was through the cancer registries and the last update of
vital status took place in December 2009. Deaths were divided into
those from prostate cancer and those from other causes, according
to WHO standardised criteria (WHO, 2010). National ethics
approval was obtained from the Northern Multicentre Research
Ethics Committee, followed by local ethics committee approval at
each of the collaborating hospitals.
Ki-67 immunohistochemistry. Diagnostic formalin-fixed paraf-
fin-embedded (FFPE) needle biopsy tissue blocks and slides (where
available) were requested. Areas of cancer were marked and those
with adequate tumour tissue available were microarrayed, by
excising the tumour tissue with spaced blades and positioning it in
a preformed donor block, as given in detail elsewhere (McCarthy
et al, 2011).
Tissue microarray (TMA) sections were immunoassayed for
Ki-67 using MIB-1 antibody, DAKO, Carpinteria, CA, USA, as
detailed previously (Berney et al, 2009). Briefly, cells were scored in
a semiquantitative manner, by an expert prostatic pathologist with
normal tonsil as a positive control, and the percentage of positive
cells was estimated as the proportion of Ki-67 stained malignant
cells, in a manner similar to that used in routine pathology
departments for the assessment of proliferation index in other
organs. All nuclear immunostaining was recorded as positive and
was clearly either strongly positive or negative. Where multiple
cancer cores per patient were stained, the maximum value
percentage staining (Ki-67 score) was used for analysis. These
were practical decisions to make the technique robust for any
pathology laboratory with experience in immunohistochemistry
and allow results to be directly comparable to our previous work.
Statistical analysis. The primary end point was time to death from
prostate cancer, which was analysed using a Cox proportional
hazards model. Observations were censored on the date of last follow-
up, or at death from other causes. Covariates included centrally
reviewed Gleason score, baseline PSA value, clinical stage, extent of
cancer (proportion of positive cores), age at diagnosis, and Ki-67.
The PSA concentration was modelled as the natural logarithm
of (1þPSA (ngml 1)), Ki-67 as a dichotomous variable (p10%,
410%) and Gleason scores were grouped into o7, ¼ 7, and 47,
for the primary analysis. We combined Gleason 3þ 4 and 4þ 3,
because they showed little difference in our previous analysis
(Cuzick et al, 2006).
All P-values were two-sided and 95% CIs and P-values, obtained
from partial likelihoods of proportional hazards models, were
based on w2 statistics with 1 degree of freedom, unless otherwise
indicated. The main assessment was a univariate analysis of the
association between death from prostate cancer and Ki-67 score.
A multivariate Cox proportional hazards model was used to
measure the added prognostic information after adjustment for the
baseline variables. This was measured as the decrease in the
likelihood ratio w2 when the Ki-67 score was omitted from a model
containing it and the other relevant baseline clinical and
pathological variables. Statistical analyses were done with STATA
(version 11.2, StataCorp, College Station, TX, USA).
RESULTS
The derivation of the cohort is shown in Figure 2 and 293 men
were available for analysis. The mean age at diagnosis was 69.6
years and during follow-up (mean 9.03 years; maximum 19.4
years), 217 (74%) men had died, 91 of prostate cancer,
corresponding to 31% of the total cohort.
A total of 339 cores, from 293 patients, comprising one (n¼ 258
(88%)) to three (n¼ 7 (2%)) per patient, were stained for Ki-67.
The maximum percent of cancerous cells staining per patient was
evaluated; 106 (36%) scored as 1%, 87 (30%) as 5%, 31 (11%) as
Table 1. Published reports of the prognostic value of Ki-67 in multivariate analyses with Hazard ratio’s (HR) after adjustment for covariates
Reference End point Cohort type Cohort size Cutoff (%) P-value HR (95% CIs) Covariates
Stattin et al (1997) PCS TURP, WW 125 3 0.0023 2.51 (1.39, 4.53) G T A
Li et al (2004) PCS RX 108 3.5 0.009 4.24 (1.43, 12.57) G T Tx
Pollack et al (2004) PCS RX 496 CONT 0.0001 3.64 (2.15, 6.16) G T P Tx
Pollack et al (2004) PCS RX 496 7.1 0.0174 2.07 (1.14, 3.76) G T P Tx
Berney et al (2009) PCS TURP, WW 685 5 0.0003 1.83 (1.33, 2.53) G P Px
Khor et al (2009) PCS RX 637 11.3 0.0007 2.35 (1.43, 3.85) G T A Tx
Fisher et al (this paper) PCS BX, WW 293 10 0.011 2.66 (1.36, 5.2) G P
Sebo et al (2002) PCR RP 454 CONT 0.008 1.64 (1.14, 2.36) G Px
Cowen et al (2002) PCR RX 106 3.5 0.003 2.8 (1.4, 5.4) G P T
Rubin et al (2002) PCR RP 88 CONT 0.047 1.49 (1.01, 2.2) G P Px
Pollack et al (2003) PCR RX 64 CONT 0.04 1.17 (1.02, 1.35) G P T bax/bcl-2
Pollack et al (2004) PCR RX 496 CONT 0.045 1.5 (1.01, 2.23) G P T Tx
Rubio et al (2005) PCR RP 91 5 0.006 3.6 (1.4, 8.9) G
Laitinen et al (2008) PCR RP 181 16 0.013 1.85 (1.14, 3.01) G P T EZH2 MCM7
Gunia et al (2008) PCR RP 528 5 0.048 1.62 (1.01, 2.61) G P T Px
Zellweger et al (2009) PCR BX, RP 279 10 0.008 4.41 (1.5, 13.2) G
Abbreviations: A¼ age; BX¼needle biopsy; CI¼ confidence interval; CONT¼ continuous; G¼Gleason grade; P¼prostate-specific antigen; PCS¼prostate cancer-specific survival;
PCR¼prostate cancer recurrence; Px¼pathological features; RP¼ radical prostatectomy; RX¼ radiotherapy; T¼ clinical stage; Tx¼ treatment; TURP¼ transurethral resection of the prostate;
WW¼watchful waiting.
Prognostic value of Ki-67 for prostate cancer death BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2012.598 273
10%, 16 (5%) as 410%, and 53 (18%) as 0 (Figure 3), and the
mean Ki-76 score was 3.99%. Ki-67 score was significantly
correlated with Gleason score, but not PSA or initial treatment
(Table 2).
Ki-67 score was analysed as a binary variable for its prognostic
value as a biomarker for prostate cancer-specific survival.
In univariate analysis, Gleason score, PSA, extent of disease, age
at diagnosis, and Ki-67 score were all significant predictors of
prostate cancer death (Table 3). Kaplan–Meier survival curves for
Ki-67 in three groups (Figure 4) showed little difference between
the two highest survival groups (p5% and 45 to p10%) and
these were combined to form a dichotomous variable with a cutoff
of p10% which gave an HR¼ 3.42 (1.76, 6.62), w2 (1 df)¼ 9.8,
P¼ 0.002. The majority of deaths (81) and the corresponding 277
cases were in the low Ki-67 groups with 10 deaths (16 cases)
belonging to those with a high level Ki-67 score (410%) (Table 3).
We also assessed Ki-67 as a continuous variable (log scale) and as a
dichotomous variable with 5% cutoff point, but results were
similar.
In multivariate analysis, the dichotomous Ki-67 variable
(p10%, 410%) added significant predictive information to that
provided by Gleason score and PSA alone (HR¼ 2.78 (1.42, 5.46),
w2 (1 df)¼ 7.0, P¼ 0.008) (Table 3). Covariates extent of disease
and age were much less informative and excluded from the final
model as they did not add significant predictive value. In clinical
subgroups based on Gleason score or PSA, no heterogeneity was
seen (Figure 5).
DISCUSSION
Although Ki-67 is the most studied of any immunochemical
biomarker in prostate cancer, to our knowledge this is the first
study to assess Ki-67 in conjunction with other known prognostic
factors in a needle biopsy cohort of conservatively managed
prostate cancers, with long-term survival data. Evidence from a
large number of other studies shows that it is an independent
significant prognostic marker in multivariate analysis of prostate
cancer progression and death, but this is primarily in cohorts of
patients treated by radical therapies.
This study shows that Ki-67 remains an important prognostic
factor in multivariate analysis in a needle biopsy cohort, and can
improve predictions of disease-specific survival based on Gleason
score and PSA alone. There was no evidence for heterogeneity
according to Gleason score or PSA, but results were not as strong
as those seen previously in the TURP cohort (Berney et al, 2009).
There may be several reasons for this. Prostate cancer is a
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Figure 3. Distribution of Ki-67 score, in diagnostic needle biopsy tissue
from a conservatively managed cohort of 293 men.
Table 2. Cross-tabulation of Ki-67 staining (% cells) with Gleason score
and baseline PSA level (n¼ 293)
Variable Ki-67
Correlation v2
(P-value)
0 1 5 10 20þ Total
Gleason score 31.6 (o0.001)
o7 17 44 17 5 1 84
7 23 44 45 17 4 133
47 13 18 25 9 11 76
Baseline PSA (ngml1) 8.87 (0.92)
p4 2 4 1 1 0 8
44–10 9 24 12 3 2 50
410–25 19 38 33 14 6 110
425–50 13 23 24 7 3 70
450–100 10 17 17 6 5 55
Total 53 106 87 31 16 293
Abbreviations: w2¼ chi-square; PSA¼prostate-specific antigen.
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heterogeneous disease and sampling the various regions of cancer
is important. This is routinely performed in studies examining RP
specimens. The TURP specimens examined in our previous study
allowed three tumour foci to be sampled in the vast majority of
cases, thus allowing Ki-67 assessment in multiple regions of
tumour. However, needle biopsies sample much less of the prostate
cancer than TURP specimens and there wereo100 tumour cells in
some biopsies. Also, because the biopsies were performed before
1997, most of the cohort consisted of only between one and four
cores per patient and very few had sextant prostatic sampling. This
is therefore a limited sample including far fewer biopsies than the
now minimum recommended guidelines for prostate cancer
biopsy, leading to an inevitable lack of tissue. Better results may
Table 3. Univariate and multivariate analysis for time to death from prostate cancer in a conservatively managed needle biopsy cohort (n¼293)
Univariate Multivariate (G, PSA, Ki-67)
Variable D/N Hazard ratio (95% CI) Hazard ratio (95% CI)
Gleason score
o7 15/84 1 (ref) 1 (ref)
7 44/133 2.35 (1.30, 4.22) 1.96 (1.08, 3.55)
47 32/76 4.57 (2.46, 8.48) 3.20 (1.69, 6.07)
w2¼ 25.5 (Po0.001)a w2¼ 13.7 (Po0.0001)
PSA (log(1þPSA) (ngml1))
91/293 1.98 (1.50, 2.60) 1.75 (1.31, 2.32)
w2¼24.6 (Po0.001) w2¼ 15.2 (Po0.0001)
Ki-67 groups (%)
p10 81/277 1 (ref) 1 (ref)
410 10/16 3.42 (1.76, 6.62) 2.66 (1.36, 5.19)
w2¼9.8 (P¼0.002) w2¼6.5 (P¼ 0.011)
Extent of disease (%)b
o50 11/50 1.00
X50 to o100 22/86 1.49 (0.72, 3.07)
100 53/130 2.42 (1.26, 4.65)
w2¼9.6 (P¼0.002)
Age at diagnosis (years)
91/293 1.05 (1.00, 1.10)
w2¼4.3 (P¼0.039)
Abbreviations: CI¼ confidence interval; D¼number of deaths; G¼Gleason score; N¼number of cases; PSA¼prostate specific antigen; w2¼ chi-square; ref¼ reference category.
aAll w2 values are for trend and on 1 degree of freedom.
bProportion of positive cores.
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be achievable with modern diagnostic methods and current
guidelines, where 12 or more cores are taken that would be more
indicative of the overall cancer burden and the most aggressive
focus of tumour is more likely to be sampled.
There are a number of issues that need to be considered before
recommending routine Ki-67 assessment of diagnostic specimens.
As with all IHC assays, there is considerable potential for variation
in Ki-67 IHC staining. Many of these points have been discussed
within the breast cancer context (Dowsett et al, 2011). Variations
in ischaemic time or formalin fixation may affect the amount of
Ki-67 staining seen in prostate tissue similar to many other IHC
assessments (Havelund et al, 2012). However, in this study, as
Ki-67 IHC staining has been performed on biopsy samples of
uniform thickness, formalin fixation occurs in a relatively
controlled fashion and there is minimal ischaemic time. This is
more of a problem in RP specimens where penetration of formalin
may vary throughout the specimen.
Speed of processing the sample into wax embedded blocks also
may influence immunostaining. Samples used in this study were
collected from UK pathology laboratories, where samples taken to
diagnose cancer are normally processed promptly and not left in
formalin for longer than 48 h. However, this is an assumption.
Immunohistochemical staining can vary from run to run. In this
study, we were able to assay the total cohort for Ki-67 using TMAs and
fewer runs were needed than to stain each individual core. However, if
Ki-67 IHC staining is to be used on a routine basis, this would not be
possible. Variations in techniques are undoubtedly important (Fasanella
et al, 2002) and a consensus similar to that recently achieved in breast
cancer will be necessary if the technique is to move into the clinical
sphere (Dowsett et al, 2011, Mengel et al, 2011).
In addition, this study has not dealt with the issue of inter-
observer variation, which is significant in many pathological data:
even including well-accepted pathological assessments such as
Gleason score. The fact that Ki-67 assessment is robust in so many
studies suggests that, similar to Gleason score, it will be robust
when applied clinically.
Here, we scored Ki-67 in a semiquantitative manner, easily
applicable in a routine pathology laboratory. We did not use
computer-based systems as compared with other solid cancers,
prostatic cancer is very difficult to identify by these methods. This
is due to the subtle nature of the pleomorphism seen in prostatic
cancers compared with normal glands, and the frequent inter-
mingling of benign and malignant glands, as well as the presence of
abundant stroma in many cases. The tiny nature of these samples
would have made this an even greater challenge. Our group has
previously reported both quantitative and semiquantitative meth-
ods to assess Ki-67 positivity (Berney et al, 2009). As the simpler
method proved as informative as the more laborious quantitative
methodology, it was used in this series. It is also more likely to be
adopted in routine practice.
The stepwise scoring system provided several distinct values
that could be implemented as cutoff points and in this needle
biopsy cohort, a 10% cutoff was found to provide useful additional
prognostic information to that provided by Gleason score and PSA.
The Ki-67 dichotomous variable with a 10% cutoff was more
prognostic for prostate cancer death than the 5% cutoff reported in
our previous TURP cohort and matches the 10% cutoff reported in
a needle biopsy cohort by Zellweger et al (2009), for biochemical
recurrence.
Commercial tests that utilise morphology, immunochemistry of
prostate adenocarcinoma biomarkers, or RNA analysis are in
development, but are much more technically demanding. One such
test (CCP score) has recently been shown to be highly predictive of
mortality in TURP and needle biopsy cohorts and in a RP cohort
(where prediction of biochemical recurrence was also observed)
(Cuzick et al, 2011, 2012). While IHC measurement of Ki-67 was
substantially less predictive than the mRNA-based CCP score, it
may have a role in instances where the CCP score is not feasible or
affordable.
Future studies will include the assessment of intra-observer
variation, and the utilisation of a larger and more contempora-
neous series of conservatively treated prostate cancers.
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